Overview

Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT)

Status:
Not yet recruiting

Trial end date:
2023-11-01

Target enrollment:

Participant gender:

Summary

This study will see how long it takes for white blood cell counts to return to normal in people with multiple myeloma (MM) who receive plinabulin and pegfilgrastim after undergoing an autologous hematopoietic stem cell transplant (AHCT).

Phase:

Phase 2

Details

Lead Sponsor:

Memorial Sloan Kettering Cancer Center

Collaborator:

BeyondSpring Pharmaceuticals Inc.